Table 1.
Patient characteristics and treatment.
| Percent of Patients | |
|---|---|
| (n = 44) | |
| Age (years): Median 71.5 (57-84) | |
| 50-59 | 6.8% (3) |
| 60-69 | 29.5% (13) |
| 70-79 | 47.7% (21) |
| >80 | 15.9% (7) |
| Race | |
| White | 52.3% (23) |
| Black | 45.5% (20) |
| Other | 2.3% (1) |
| BMI | |
| 18.5-24.9 | 34.1% (15) |
| 25.0-29.9 | 34.1% (15) |
| >30.0 | 31.8% (14) |
| Prior urologic procedure | |
| Yes | 2.3% (1) |
| No | 97.7% (43) |
| Charlson Comorbidity Index | |
| 0 | 34.1% (15) |
| 1-2 | 59.1% (26) |
| >2 | 6.8% (3) |
| Anticoagulation/antiplatelet | |
| Warfarin | 45.5% (20) |
| Clopidogrel | 34.1% (15) |
| Rivaroxaban | 9.1% (4) |
| Enoxaparin | 2.3% (1) |
| Other | 4.6% (2) |
| Combination | 4.5% (2) |
| T stage | |
| T1c-T2a | 81.8% (36) |
| T2b-T2c | 18.2% (8) |
| Gleason Score | |
| 6 | 31.8% (14) |
| 7 | 59.1% (26) |
| 8-9 | 9.1% (4) |
| Risk group (D’Amico) | |
| Low | 20.5% (9) |
| Intermediate | 63.6% (28) |
| High | 15.9% (7) |
| Hormone Therapy | |
| Yes | 11.4% |
| No | 88.6% |
| SBRT dose | |
| 35 | 31.8% (14) |
| 36.25 | 68.2% (30) |